Viatris Inc Asset Resilience Ratio
Viatris Inc asset resilience ratio. Viatris Inc (VTRS) has an Asset Resilience Ratio of 1.48% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Viatris Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Viatris Inc (1999–2025)
Asset resilience ratio of Viatris Inc from 1999 to 2025. This chart shows how Viatris Inc's Asset Resilience Ratio has changed over time. See Viatris Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Viatris Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Viatris Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $519.80 Million | 1.48% |
| Total Liquid Assets | $519.80 Million | 1.48% |
Asset Resilience Insights
- Limited Liquidity: Viatris Inc maintains only 1.48% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Viatris Inc Industry Peers by Asset Resilience Ratio
Compare Viatris Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Viatris Inc Asset Resilience Ratio by Year (1999–2025)
Viatris Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Viatris Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.29% | $106.40 Million | $37.19 Billion | -0.57pp |
| 2024-12-31 | 0.86% | $355.10 Million | $41.50 Billion | +0.45pp |
| 2023-12-31 | 0.40% | $192.50 Million | $47.69 Billion | -0.02pp |
| 2022-12-31 | 0.43% | $212.60 Million | $50.02 Billion | 0.00pp |
| 2021-12-31 | 0.43% | $233.80 Million | $54.84 Billion | +0.10pp |
| 2020-12-31 | 0.33% | $203.50 Million | $61.55 Billion | -0.02pp |
| 2019-12-31 | 0.35% | $109.10 Million | $31.26 Billion | +0.17pp |
| 2018-12-31 | 0.18% | $57.50 Million | $32.73 Billion | -0.13pp |
| 2017-12-31 | 0.31% | $110.60 Million | $35.81 Billion | +0.07pp |
| 2016-12-31 | 0.24% | $83.80 Million | $34.73 Billion | 0.00pp |
| 2015-12-31 | 0.24% | $54.00 Million | $22.27 Billion | +0.06pp |
| 2014-12-31 | 0.18% | $28.20 Million | $15.82 Billion | +0.00pp |
| 2013-12-31 | 0.18% | $27.00 Million | $15.29 Billion | -0.02pp |
| 2012-12-31 | 0.19% | $22.93 Million | $11.93 Billion | -0.07pp |
| 2011-12-31 | 0.26% | $30.69 Million | $11.60 Billion | +0.01pp |
| 2010-12-31 | 0.25% | $29.09 Million | $11.54 Billion | 0.00pp |
| 2009-12-31 | 0.26% | $27.56 Million | $10.80 Billion | -0.15pp |
| 2008-12-31 | 0.41% | $42.26 Million | $10.39 Billion | -0.40pp |
| 2007-12-31 | 0.80% | $91.36 Million | $11.35 Billion | -3.29pp |
| 2006-12-31 | 4.10% | $174.21 Million | $4.25 Billion | -15.58pp |
| 2005-12-31 | 19.67% | $368.00 Million | $1.87 Billion | -11.71pp |
| 2004-12-31 | 31.39% | $670.35 Million | $2.14 Billion | +0.33pp |
| 2003-12-31 | 31.06% | $585.45 Million | $1.89 Billion | +6.54pp |
| 2002-12-31 | 24.52% | $427.90 Million | $1.75 Billion | -3.70pp |
| 2001-12-31 | 28.22% | $456.27 Million | $1.62 Billion | +24.42pp |
| 2000-12-31 | 3.80% | $55.72 Million | $1.47 Billion | -3.62pp |
| 1999-12-31 | 7.42% | $99.56 Million | $1.34 Billion | -- |
About Viatris Inc
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and … Read more